December 8, 2009
EUSTIS, Fla.Valensa International signed an exclusive, long-term global supply ingredient with Olso, Norway-based Aker BioMarine; Valensa will incorporate Superba Krill Oil in its proprietary joint health and eye health formulations. The companies will also jointly perform clinical studies to document the benefits of Superba Krill oil in Valensas patented and patent-pending products.
We are very excited about the opportunity to work with Valensa, and this agreement marks the entry of Superba Krill Oil into the joint health market, the largest category of dietary supplements, representing $3.4 billion in the United States alone, said Matts Johansen, Aker BioMarines executive vice president of sales and marketing. As such, joint health is close to 300 percent larger than the cardiovascular health category and obviously an interesting market for us to enter into.
Valensa will use Superba Krill Oil in its condition-specific dietary supplement formulas in conjunction with several of its own proprietary ingredients, such as Zanthin® Natural Astaxanthin. In a statement issued by Valensa, CEO Rudi E. Moerck, said, The increased potency of formulas containing krill [that allow] formulators and marketers to reduce the size of their softgels and reduce the pill burden on people is one of the key reasons for using Superba Krill Oil in Valensas proprietary formulations.
You May Also Like
Sep 28, 2023
Innovation in stress and sleep management: Holixer™– white paperSep 22, 2023
Cognitive health growth comes out on top: A range of solutions for diverse needs continue to emerge and win – product development guideSep 25, 2023
LifeVantage proxy fight heats up as revenues coolSep 28, 2023
The ashwagandha root production process: Where tradition meets science – article part threeSep 21, 2023